WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998051335) METHODS OF MODULATING IMMUNE COAGULATION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1998/051335 International Application No.: PCT/CA1998/000475
Publication Date: 19.11.1998 International Filing Date: 15.05.1998
Chapter 2 Demand Filed: 10.12.1998
IPC:
A61K 38/00 (2006.01) ,A61K 48/00 (2006.01) ,C07K 16/40 (2006.01) ,C12N 9/64 (2006.01) ,G01N 33/68 (2006.01) ,G01N 33/86 (2006.01)
Applicants: LEVY, Gary[CA/CA]; CA (UsOnly)
CLARK, David, A.[CA/CA]; CA (UsOnly)
TRANSPLANTATION TECHNOLOGIES INC.[CA/CA]; 621 University Avenue, NU10-151 Toronto, M5G 2C4 Ontario, CA (AllExceptUS)
Inventors: LEVY, Gary; CA
CLARK, David, A.; CA
Agent: BERESKIN & PARR; 40th floor 40 King Street West Toronto, Ontario M5H 3Y2, CA
Priority Data:
60/046,53715.05.1997US
60/061,68410.10.1997US
Title (EN) METHODS OF MODULATING IMMUNE COAGULATION
(FR) METHODES DE MODULATION DE LA COAGULATION IMMUNE
Abstract:
(EN) Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.
(FR) L'invention concerne de nouvelles méthodes permettant d'induire une coagulation immune au moyen de nouveaux anti-corps et composés. On a identifié une protéine Fgl2 ayant une activité prothrombinase directe. Des inhibiteurs de Fgl2 sont utiles dans la prévention et dans le traitement de maladies nécessitant une réduction de la coagulation immune notamment dans les affections bactériennes et virales, le rejet d'allogreffes et d'hétérogreffes, la glomérulonéphrite, le cancer, un certain nombre de maladies gastrointestinales et la perte du foetus.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)